R. Dyer

发表

In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.

R. D. Dyer, P. Young, J. Summers, 1987, Journal of medicinal chemistry.

Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.

R. D. Dyer, A. Sercel, K. Chan, 1999, Journal of medicinal chemistry.

Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Substituted Di-tert-butylphenols as a Novel Class of Potent, Selective, and Orally Active Cyclooxygenase-2 Inhibitors. 1. Thiazolone and Oxazolone Series1

R. D. Dyer, A. Sercel, R. Gilbertsen, 1999 .

Nuclear factor-kappaB mediated inhibition of cytokine production by imidazoline scaffolds.

R. D. Dyer, A. D. Jones, R. W. Henry, 2009, Journal of medicinal chemistry.

Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.

R. D. Dyer, Adam R. Johnson, R. Dyer, 2008, Journal of medicinal chemistry.

Structure-activity analysis of a class of orally active hydroxamic acid inhibitors of leukotriene biosynthesis.

R. D. Dyer, P. Young, J. Summers, 1988, Journal of medicinal chemistry.

Orally active hydroxamic acid inhibitors of leukotriene biosynthesis.

R. D. Dyer, P. Young, J. Summers, 1988, Journal of medicinal chemistry.

1,3,4-Oxadiazole, 1,3,4-thiadiazole, and 1,2,4-triazole analogs of the fenamates: in vitro inhibition of cyclooxygenase and 5-lipoxygenase activities.

R. D. Dyer, D. Boschelli, R. Dyer, 1993, Journal of medicinal chemistry.

Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats.

R. D. Dyer, R. Gilbertsen, R. Dyer, 1998, The Journal of pharmacology and experimental therapeutics.

Catalytic Activities and Substrate Specificity of the Human Membrane Type 4 Matrix Metalloproteinase Catalytic Domain*

R. D. Dyer, Q. Ye, R. Dyer, 1999, The Journal of Biological Chemistry.

Synthesis of reversed hydroxamic acids of indomethacin: dual inhibitors of cyclooxygenase and 5-lipoxygenase

R. D. Dyer, D. Boschelli, R. Dyer, 1992 .

Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons.

R. D. Dyer, K. Maddipati, J. Johnson, 1995, Archives of biochemistry and biophysics.

Suppression of murine T-cell mitogenesis by metabolic products of arachidonic acid.

K. Mcleish, R. Dyer, D. Senitzer, 1982, Journal of immunopharmacology.

1-Phenyl-[2H]-tetrahydropyridazin-3-one, A-53612, a selective orally active 5-lipoxygenase inhibitor

P. Young, D. Albert, J. Bouska, 1992 .

Structural analysis of 2-aryl-1,3-dione compounds as inhibitors of 5-lipoxygenase

R. D. Dyer, P. Young, R. Dyer, 1992 .

Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects*

R. D. Dyer, Adam R. Johnson, Chunhong Yan, 2007, Journal of Biological Chemistry.

The Role of Arachidonic Acid in the Secretion of the Amyloid Precursor Protein (APP) a

R. D. Dyer, R. T. Carroll, M. Emmerling, 1996, Annals of the New York Academy of Sciences.

The pharmacologic effects of 5-[3,5-bis(1,1-dimethylethyl)-4- hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione, choline salt (CI-986), a novel inhibitor of arachidonic acid metabolism in models of inflammation, analgesia and gastric irritation.

M. D. Mullican, R. Dyer, D. T. Connor, 1994, Prostaglandins.

Hydroxamic acid inhibitors of 5-lipoxygenase.

R. D. Dyer, J. Summers, H. Mazdiyasni, 1987, Journal of medicinal chemistry.

Structure-activity relationships of the pyridazinone series of 5-lipoxygenase inhibitors

P. Young, D. Albert, R. Dyer, 1992 .

Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)- 4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity.

R. D. Dyer, R. Sorenson, R. Dyer, 1994, Journal of medicinal chemistry.

Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally-active, nonulcerogenic antiinflammatory agents.

R. D. Dyer, M. D. Mullican, M. Wilson, 1993, Journal of medicinal chemistry.

Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-lipoxygenase and cyclooxygenase inhibitors.

R. Dyer, D. T. Connor, P. Unangst, 1992, Journal of medicinal chemistry.

Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-lipoxygenase and cyclooxygenase inhibitors.

R. D. Dyer, R. Dyer, D. T. Connor, 1992, Journal of medicinal chemistry.

Slow-binding inhibition of human prostaglandin endoperoxide synthase-2 with darbufelone, an isoform-selective antiinflammatory di-tert-butyl phenol.

R. D. Dyer, M. Marletta, R. Dyer, 2001, Biochemistry.

Synthesis and Biological Evaluation of 5-((3,5-Bis(1,1-dimethylethyl)- 4-hydroxyphenyl)methylene)oxazoles, -thiazoles, and -imidazoles: Novel Dual 5-Lipoxygenase and Cyclooxygenase Inhibitors with Antiinflammatory Activity.

R. D. Dyer, R. Sorenson, R. Dyer, 1994 .

Oxazole, thiazole, and imidazole derivatives of 2,6-di-tert-butylphenol as dual 5-lipoxygenase and cyclooxygenase inhibitors

R. D. Dyer, R. Sorenson, R. Dyer, 1993 .

Quantitative structure-activity relationships of 5-lipoxygenase inhibitors. Inhibitory potency of pyridazinone analogues.

Y. Martin, R. Dyer, D. W. Brooks, 1994, Journal of pharmaceutical sciences.

Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.

R. D. Dyer, J. Summers, H. Mazdiyasni, 1990, Journal of medicinal chemistry.

Cyclooxygenase and 5-lipoxygenase inhibitory activity of 2,6 di-t-butylphenols linked by a sulfur atom to 1,3,4-thiadiazoles and 1,3,4-oxadiazoles

D. Boschelli, R. Dyer, D. T. Connor, 1993 .

Synthesis and 5-lipoxygenase inhibitory activity of 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid analogues.

R. Dyer, D. W. Brooks, G. Carter, 1987, Journal of medicinal chemistry.

Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.

L. Johnson, A. Pavlovsky, R. Dyer, 2000, Journal of medicinal chemistry.

Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.

Adam R. Johnson, K. Aston, A. Wittwer, 2010, Bioorganic & medicinal chemistry letters.

Structural requirements for the inhibition of 5-lipoxygenase by 15-hydroxyeicosa-5,8,11,13-tetraenoic acid analogues.

R. D. Dyer, Y. Martin, F. Haviv, 1987, Journal of medicinal chemistry.

4-hydroxythiazole inhibitors of 5-lipoxygenase.

R. D. Dyer, R. Dyer, D. W. Brooks, 1991, Journal of medicinal chemistry.

5-lipoxygenase inhibitory activity of zileuton.

R. D. Dyer, P. Young, D. Albert, 1991, The Journal of pharmacology and experimental therapeutics.

Attenuation of diet‐induced atherosclerosis in rabbits with a highly selective 15‐lipoxygenase inhibitor lacking significant antioxidant properties

R. D. Dyer, B. Tait, A. Daugherty, 1997, British journal of pharmacology.

Prostaglandin synthesis by vascular smooth muscle cells is stimulated by bradykinin, prazosin and hydralazine.

R. D. Dyer, R. Dyer, J. Huttner, 1981, Progress in lipid research.

Characterization of elevated i-PGE2 in human female urine.

R. Dyer, P. Mulrow, S. Y. Tan, 1981, Progress in lipid research.

R. D. Dyer, A. Sercel, K. Chan, 1999, Journal of medicinal chemistry.

Catechol based inhibitors of 15-lipoxygenase

B. Tait, R. Dyer, B. Roth, 1996 .

propane : An Iodinated Radioligand That Specifically Labels the Agonist High-Affinity State of 5-HT 2 Serotonin Receptors

P. Young, J. Summers, B. Gunn, 2022 .

Eicosatetraenehydroxamates: inhibitors of 5-lipoxygenase

R. D. Dyer, R. Dyer, G. Carter, 1985 .

Conversion of NSAIDS into balanced dual inhibitors of cyclooxygenase and 5-lipoxygenase

D. Boschelli, R. Dyer, D. T. Connor, 1992 .

Nonsteroidal antiinflammatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase.

R. D. Dyer, R. Dyer, D. Flynn, 1990, Journal of medicinal chemistry.

Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors.

R. D. Dyer, R. Dyer, D. Bornemeier, 1995, Bioorganic & medicinal chemistry.